Type 1 diabetes (T1D) is increasing in incidence and predictable with measurement of serum islet autoantibodies (iAb) years prior to clinical disease onset. Identifying iAb positive individuals reduces diabetic ketoacidosis and identifies individuals for T1D prevention trials. However, large scale screening for iAb remains challenging as assays have varying sensitivities and specificities, insulin autoantibodies remain difficult to measure and venipuncture is generally required to obtain serum. We developed an approach to reliably measure all four major iAb, including insulin autoantibodies, from dried blood spots (DBS) on filterpaper. By spiking iAb positive serum into iAb negative whole blood in a dose titration, we optimized the conditions for autoantibody elution from filter paper as measured by fluid phase radioimmunoassays. After assessing stability of measuring iAb from DBS over time, we then screened iAb from DBS and the corresponding serum in new-onset T1D (n = 52), and controls (n = 72) which included first-degree relatives of T1D patients. iAb measured from eluted DBS in new-onset T1D strongly correlated with serum measurements (R 2 = 0.96 for mIAA, GADA = 0.94, IA-2A = 0.85, ZnT8A = 0.82, p<0.01 for each autoantibody). There were no false positives in control subjects, and 5/6 with previously unknown iAb positivity in sera were detected using DBS. With further validation, measuring iAb from DBS can be a reliable method to screen for T1D risk.
Introduction
The incidence of Type 1 diabetes (T1D), the immune mediated form of diabetes, has increased dramatically worldwide over the past two decades. [1] T1D can be identified prior to clinical onset of symptoms by measuring serum islet autoantibodies (iAb) to insulin (mIAA), glutamic decarboxylase (GADA), islet antigen (IA-2A), and zinc transporter (ZnT8A). [2] The presence of two or more iAb confers significant risk for disease development as approximately 70% of these children develop T1D within 10 years and have close to a 100% lifetime risk. [3] In Colorado, nearly half of children who develop T1D present in diabetic ketoacidosis, which is a life-threatening condition that occurs with prolonged insulin deficiency. [4] DKA confers significant risk for cerebral edema, functional changes in the brain, long-term neurocognitive deficits and even death. [5] [6] [7] The American Diabetes Association now recommends that relatives of patients with T1D be screened for islet autoimmunity through an available clinical research trial. [8] Monitoring for the development of islet autoimmunity and T1D in firstdegree relatives (FDR) and individuals with high risk HLA-DQ-DR genotypes has been done in a number of prospective longitudinal studies with serial iAb measurements. [9] [10] [11] [12] These individuals have a lower incidence of life-threatening diabetic ketoacidosis and also have the opportunity to participate in T1D prevention trials. [13] [14] [15] However, 85% of individuals who develop T1D do not have a family history and are not identified until they have clinical symptoms. Many prevention trials have focused on using preparations of insulin (subcutaneous, nasal and oral) in people at risk to delay T1D onset. [16, 17] Notably, a post-hoc analysis from the Diabetes Prevention Trial-Type 1 oral insulin trial found that treatment responders, defined by high titer insulin autoantibodies prior to treatment, had delayed progression to T1D. [18] A subsequent trial is underway to replicate these findings. iAb are routinely measured from serum obtained by venipuncture, which places limitations on large scale screening for early T1D identification.
Most successful and widely integrated screening and disease surveillance programs obtain samples from dried blood spots (DBS) on filter paper. The use of DBS to screen newborn infants for congenital metabolic disease has been in place for over fifty years. [19] DBS are now routinely used to screen for diseases such as hepatitis and HIV in developing countries. [20] To date, success in measuring iAb from DBS on filter paper has been limited, and no study has successfully measured all four major iAb from DBS on filter paper. [21, 22] However, a recent study conducted through the National Institute of Health sponsored TrialNet Pathway to Prevention Study collected both DBS and serum for iAb determination using fluid-phase radioimmunoassays (RIA) and found good concordance between DBS and serum measurements for GADA, IA-2A, and ZnT8A; however, mIAA were not measured [23] . Insulin autoantibodies have historically been difficult to measure in serum obtained from venipuncture and especially by alternative collection methods. Nevertheless, the need exists to measure insulin autoantibodies as they are often the first autoantibody to appear in young children, higher levels correlate with a shorter time to clinical disease onset and many prevention trials have focused on insulin therapies [24] [25] [26] [27] .
In the current study, we optimized the conditions to elute autoantibodies from DBS on filter paper, assessed stability over time, and then measured iAb in new-onset T1D patients (n = 52) and screened for iAb in controls (n = 72), which included both healthy individuals and FDRs. Eluted DBS iAb measurements were compared to serum measurements using fluid-phase RIAs. We report the reliable measurement of all four iAb, including insulin autoantibodies, from DBS on filter paper.
Materials and Methods

Subjects
The clinical investigation in this study was conducted in accordance with the Declaration of Helsinki principles. Study approval was provided by the Colorado Multiple Institutional Review Board, and written informed consent was received from participants prior to inclusion in the study. Subjects were recruited from the Barbara Davis Center for Diabetes clinics. Newonset T1D subjects were recruited at diagnosis or during standard follow-up visits. Controls were healthy volunteers and FDRs with an unknown iAb status.
Serum iAb measurements. Biochemical autoantibodies (mIAA, GADA, IA-2A, ZnT8A) were measured with fluid-phase RIAs at the Barbara Davis Center as previously described. [28] [29] [30] The mIAA assay was performed with a competition RIA. Levels of autoantibodies are expressed as a DK unit (NIDDK unit) from a standard curve for GADA and IA-2A or an index for mIAA and ZnT8A [index = (CPM sample-CPM negative control)/(CPM positive control-CPM negative control)] where CPM is counts per minute, with each antibody having its own positive standard for calculations. The intra-assay coefficient of variance for mIAA is 5.2%, GADA 4.9%, IA-2A 4.3% and ZnT8A 3.2%. The inter-assay coefficient of variance for mIAA is 16%, GADA 8.3%, IA-2A 9.9% and ZnT8A 10.4%. Positive cut-off values for serum RIA were index 0.010 for mIAA, 20 DK units for GADA, 5 DK units for IA-2A, and index 0.020 for ZnT8A, which are accepted and well validated cut-offs used to define iAb positivity by RIA both clinically and in large clinical research trials such as those conducted through Type 1 Diabetes TrialNet.
iAb measurements from DBS on filter paper
For experiments optimizing iAb measurement from DBS on filter paper, high titer iAb positive serum was spiked into iAb negative whole blood, placed onto Whatman #903 filter paper and allowed to completely dry. This created an autoantibody dose titration from DBS on filter paper with the corresponding serum isolated for each condition. To elute iAb, two 6mm spots were punched from each DBS, and a single punch was placed in each well of a plastic 96-well flat bottom non-protein binding plate (Corning). Elution buffer (65 μl of 20mM Tris-HCl (pH 7.4), 150mM NaCl, 0.1% bovine serum albumin, 0.15% Tween-20 and 0.1% NaN 3 ) was added to each well, and the plate was agitated for 30 minutes at room temperature and then incubated overnight at 4˚C. Eluent from the DBS was stored at -20˚C until analysis for iAb using fluidphase RIA. Each 6mm punch from a DBS was used to measure a single iAb with 30 μl of eluent required for GADA, IA-2A, and ZnT8A RIA and 40 μl of eluent for mIAA. Fluid-phase RIAs, as described above, were used to measure iAb from both serum and DBS eluent.
Stability testing was conducted in a similar manner in which iAb positive serum was spiked into iAb negative whole blood and placed onto filter paper. Three DBS samples of varying iAb concentrations were prepared for each iAb and eluted weekly over a 28 day period.
For new-onset T1D and control subjects, fresh whole blood was collected from patients via venipuncture and 75 μl of blood was applied to the center of a 1.3 cm circle on filter paper; serum was obtained from the remaining whole blood. The blood spots were dried on an open surface at room temperature and stored for up to 4 weeks. Eluent from a single 6mm DBS punch was used to measure each iAb with a RIA. The intra-assay coefficient of variance from eluted DBS samples for mIAA is 9.9%, GADA 7.9%, IA-2A 9.7% and ZnT8A 9.8%. The interassay coefficient of variance for mIAA is 14.5%, GADA 9.7%, IA-2A 11.3% and ZnT8A 6.8%, which are similar to those for serum RIA.
Statistical Analysis
Linear regression analysis was done to compare serum iAb levels to those measured from DBS on filter paper using GraphPad Prism 6.0 software. A two-tailed p value of <0.05 is considered significant. To determine sensitivity and specificity, positive cut-off values for serum were applied to DBS measurements.
Results
Measuring islet autoantibodies from dried blood spots on filter paper
To optimize and ensure successful iAb measurement from DBS on filter paper, high titer iAb positive serum was spiked into iAb negative whole blood to create a dose titration for each autoantibody. The iAb spiked blood was then placed on filter paper, and the corresponding serum isolated. Fluid-phase RIAs were used to measure iAb from both serum and DBS eluent. These experiments allowed for the evaluation of multiple variables including: eluent used for extraction, volume of eluent, plastic plate (standard, low protein binding, non-protein binding), number of DBS per well for protein extraction, incubation time in eluent, and agitation time to extract protein from filter paper. Using a non-protein binding plate, decreasing the volume of eluent per well, and agitating the sample prior to incubation optimized the measurement of iAb from DBS. Using optimized conditions, DBS iAb measurements correlated well with the corresponding serum measurements for each iAb as depicted in Fig 1 ( We next evaluated the stability of measuring iAb from DBS on filter paper over time. Similar to the spiking experiments used to optimize the elution and measurement of iAb from DBS, we made three samples for each individual iAb and placed the samples on filter paper. The DBS were stored at room temperature and each sample was eluted at weekly intervals over 
Dried blood spot measurements in new-onset T1D and controls
After establishing a method to measure iAb from DBS on filter paper, we measured iAb from both DBS on filter paper and serum from new-onset T1D patients (n = 52). Table 1 describes the demographics of this cohort, which includes predominantly adolescents (median age 14). The median time from T1D onset was 13 days, and the majority of subjects (71%) had samples collected within 3 weeks of initiating insulin therapy. 90% of new onset T1D patients had !1 iAb present and 81% had !2 iAb present. As shown in Fig 3, We then screened iAb from both DBS on filter paper and serum in healthy control subjects (n = 72) in which 34 were FDRs. Since FDRs have a higher risk for T1D than normal controls, FDRs were included in an attempt to identify individuals otherwise not known to have iAb positivity. Normal controls helped determine the likelihood of false positive iAb measurements. Table 1 includes the demographic data in which controls had a median age of 33. As depicted in Fig 4, there were no false positive DBS measurements for each iAb. Positive iAb were detected in 6 controls by serum RIA measurements. Two subjects were positive for mIAA alone by both serum RIA (index 0.019, 0.021) and DBS (index 0.010, 0.019). Another subject was GADA positive, again detected by DBS measurement. One subject was positive for all four iAb by both methods. A subject with a low level positive GADA by serum (32 DK units) was not identified by DBS. A final control subject was positive for both GADA and IA-2A by serum RIA but only positive for GADA by DBS measurement. Again, the IA-2A level was at the lower level of positivity.
Discussion
Our results demonstrate that iAb measurements from DBS on filter paper strongly correlate to serum levels. Importantly, we were able to measure insulin autoantibodies from DBS with a significant correlation to RIA serum measurements, which has historically been challenging. Our ability to successfully measure mIAA from filter paper was influenced by several factors. First, we optimized the assay by using a non-protein binding plate to limit the binding of antibody to the plate. We also determined the minimum sample volume necessary to measure all four iAb, thereby concentrating iAb in elution buffer. Finally, agitating the filter-paper samples in elution buffer improved protein elution. In addition to variables we manipulated, part of our success is due to the fact that mIAA assays and measurement have improved greatly over the last decade through the Diabetes Antibody Standardization Program [31] . Reliably measuring mIAA is important for several reasons. First, young children can be identified in the pre-symptomatic stage of T1D as mIAA are often the first iAb to develop and mIAA levels correlate with time to disease onset. [24] [25] [26] [27] Second, there is an eligibility requirement to be mIAA positive to enroll in current and upcoming oral insulin prevention trials (NCT00419562, NCT02580877). With the ability to reliably measure mIAA from DBS on filter paper, identifying young children in the early stages of T1D becomes feasible and the approach is adaptable for general population screening. It is noteworthy that one group reported good concordance between insulin antibody titers using dried capillary blood spots and serum; however, only 15 T1D subjects in their cohort were positive for insulin antibodies. [22] Our results need to be validated in a larger cohort of patients using a capillary finger-stick to obtain DBS followed by a confirmatory serum test on patients with positive iAb before DBS methodology can be widely adopted as a screening test.
Although it is important that screening tests have high sensitivity, it is also necessary to limit the false positive rate to avoid patient and economic burden. In our control group, there were no false positive measurements. We did identify 5 of 6 control subjects by DBS who had at least one positive serum iAb. The iAb not detected by DBS was near the lower limit of detection in serum. Following surveillance models used in other diseases, a screening test requires a gold standard confirmatory test. Therefore, although DBS may provide a method for first-line screening, patients who are positive require a confirmatory test with serum for iAb measurement. Using DBS on filter paper offers distinct advantages for large scale early identification of T1D risk. DBS are easy to collect and store, stable over time, easily transported by mail to a core laboratory that is proficient in measuring iAb, cost effective and have a low infectivity risk. Limitations to using DBS to measure iAb include the need to have a completely dried spot on filter paper, elution of samples for analysis, small volumes are obtained following elution and hemolysis may potentially affect results.
Measuring iAb from DBS on filter paper has the potential to be a viable alternative to serum measurements in a variety of clinical and research environments including pediatric practices, rural areas and developing countries. Now that it is feasible to measure the four conventional iAb including insulin from a minimal amount of blood dried on filter paper, validation studies are warranted to expand this approach into a general population screening test for T1D risk.
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